Korean J Dermatol.  2019 Aug;57(7):383-386.

A Case of Nivolumab-induced Cutaneous Toxicity

• Choi W
• Myung KB
• Hahn HJ
• Cheong SH

Abstract

Nivolumab is anti-programmed death 1 (PD1) receptor antibody, which can be used in the treatment of metastatic squamous cell cancer. By blocking the PD1 receptors on T cells, it enhances T-cell response against cancer cells. A 69-year-old man, who works as a farmer, presented with erythematous lichenified plaques on sun-exposed areas, such as the face, the chest, and both the forearms. Before the hospital visit, he was receiving lung cancer treatment with paclitaxel and cisplatin, but there was no improvement. Subsequently, the regimen was changed into nivolumab, and PET-CT showed decreased in cancer size. However, skin rashes developed simultaneously. It is consistent with the results of a previous study in which cutaneous side effects developed in 42% of responders compared to 7% of non-responders. Herein, we report a case of nivolumab-induced cutaneous toxicity on sun-exposed areas based on the clinical findings, including the distribution of rashes, which were improved after decreasing the nivolumab dose with literature review.

Keyword

Nivolumab; Cutaneous toxicity; Sun-exposed area

MeSH Terms

Aged
Cisplatin
Exanthema
Farmers
Forearm
Humans
Lung Neoplasms
Neoplasms, Squamous Cell
Paclitaxel
Programmed Cell Death 1 Receptor
T-Lymphocytes
Thorax
Cisplatin
Paclitaxel
Programmed Cell Death 1 Receptor